Publicly traded since August 2018 and not SBIR involved since 2011, BioNano Genomics (NASDAQ:BNGOU) is organized around nanoscale imaging and analytic platforms to analyze DNA and other genome-related peptides and proteins. The firm offers a platform to analyze the long segments of genomic DNA and other long biomolecules structural variations. Offering a nanoAnalyzer System that allows users to visualize the whole genome capturing long molecules at high resolution; and Irys System, a genome mapping system that empowers genomics researchers to discover structural variation analysis and sequence assemblies, the firm's platform provides researchers and clinicians with a picture of genomes that provide insights into how the individual components of genomes are ordered, arranged, and interact with each other. The company works with institutions in life science, translational research, molecular diagnostics, and personalized medicine. Formerly known as BioNanomatrix, Inc. management changed name to BioNano Genomics, Inc. in October 2011.